110 related articles for article (PubMed ID: 26010159)
21. Appraising cardiotoxicity associated with liposomal doxorubicin by means of tissue Doppler echocardiography end-points: rationale and design of the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study.
Lotrionte M; Palazzoni G; Natali R; Comerci G; Abbate A; Di Persio S; Biondi-Zoccai GG
Int J Cardiol; 2009 Jun; 135(1):72-7. PubMed ID: 18572266
[TBL] [Abstract][Full Text] [Related]
22. Cardiotoxicity after liposomal anthracyclines.
Young AM; Dhillon T; Bower M
Lancet Oncol; 2004 Nov; 5(11):654. PubMed ID: 15522651
[No Abstract] [Full Text] [Related]
23. Mitochondrial catastrophe during doxorubicin-induced cardiotoxicity: a review of the protective role of melatonin.
Govender J; Loos B; Marais E; Engelbrecht AM
J Pineal Res; 2014 Nov; 57(4):367-80. PubMed ID: 25230823
[TBL] [Abstract][Full Text] [Related]
24. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes.
Working PK; Newman MS; Sullivan T; Yarrington J
J Pharmacol Exp Ther; 1999 May; 289(2):1128-33. PubMed ID: 10215696
[TBL] [Abstract][Full Text] [Related]
25. Coformulated N-octanoyl-glucosylceramide improves cellular delivery and cytotoxicity of liposomal doxorubicin.
Veldman RJ; Koning GA; van Hell A; Zerp S; Vink SR; Storm G; Verheij M; van Blitterswijk WJ
J Pharmacol Exp Ther; 2005 Nov; 315(2):704-10. PubMed ID: 16040815
[TBL] [Abstract][Full Text] [Related]
26. Polyphenols, autophagy and doxorubicin-induced cardiotoxicity.
Shabalala S; Muller CJF; Louw J; Johnson R
Life Sci; 2017 Jul; 180():160-170. PubMed ID: 28478263
[TBL] [Abstract][Full Text] [Related]
27. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
[TBL] [Abstract][Full Text] [Related]
28. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
Allen TM; Mumbengegwi DR; Charrois GJ
Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
[TBL] [Abstract][Full Text] [Related]
29. The liposomal formulation of doxorubicin.
Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
[TBL] [Abstract][Full Text] [Related]
30. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet).
Leonard RC; Williams S; Tulpule A; Levine AM; Oliveros S
Breast; 2009 Aug; 18(4):218-24. PubMed ID: 19656681
[TBL] [Abstract][Full Text] [Related]
31. Targeted magnetic liposomes loaded with doxorubicin.
Pradhan P; Banerjee R; Bahadur D; Koch C; Mykhaylyk O; Plank C
Methods Mol Biol; 2010; 605():279-93. PubMed ID: 20072888
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer.
Stavridi F; Palmieri C
Expert Rev Anticancer Ther; 2008 Dec; 8(12):1859-69. PubMed ID: 19046106
[TBL] [Abstract][Full Text] [Related]
33. New chimeric advanced Drug Delivery nano Systems (chi-aDDnSs) as doxorubicin carriers.
Gardikis K; Tsimplouli C; Dimas K; Micha-Screttas M; Demetzos C
Int J Pharm; 2010 Dec; 402(1-2):231-7. PubMed ID: 20934501
[TBL] [Abstract][Full Text] [Related]
34. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
[TBL] [Abstract][Full Text] [Related]
35. Engineered peptides for the development of actively tumor targeted liposomal carriers of doxorubicin.
Shahin M; Soudy R; El-Sikhry H; Seubert JM; Kaur K; Lavasanifar A
Cancer Lett; 2013 Jul; 334(2):284-92. PubMed ID: 23073474
[TBL] [Abstract][Full Text] [Related]
36. Membrane-Loaded Doxorubicin Liposomes Based on Ion-Pairing Technology with High Drug Loading and pH-Responsive Property.
Xu H; Zhang L; Li L; Liu Y; Chao Y; Liu X; Jin Z; Chen Y; Tang X; He H; Kan Q; Cai C
AAPS PharmSciTech; 2017 Aug; 18(6):2120-2130. PubMed ID: 28028795
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of antitumor activity and cardiac toxicity of a bone-targeted ph-sensitive liposomal formulation in a bone metastasis tumor model in mice.
Dos Santos Ferreira D; Jesus de Oliveira Pinto BL; Kumar V; Cardoso VN; Fernandes SO; Souza CM; Cassali GD; Moore A; Sosnovik DE; Farrar CT; Leite EA; Alves RJ; de Oliveira MC; Guimarães AR; Caravan P
Nanomedicine; 2017 Jul; 13(5):1693-1701. PubMed ID: 28343016
[TBL] [Abstract][Full Text] [Related]
38. Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells.
Sriraman SK; Pan J; Sarisozen C; Luther E; Torchilin V
Mol Pharm; 2016 Feb; 13(2):428-37. PubMed ID: 26702994
[TBL] [Abstract][Full Text] [Related]
39. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
Skubitz KM; Blaes AH; Konety SH; Francis GS
Cancer Chemother Pharmacol; 2017 Oct; 80(4):787-798. PubMed ID: 28856562
[TBL] [Abstract][Full Text] [Related]
40. Curcumin ameliorates doxorubicin-induced cardiotoxicity by abrogation of inflammation, apoptosis, oxidative DNA damage, and protein oxidation in rats.
Benzer F; Kandemir FM; Ozkaraca M; Kucukler S; Caglayan C
J Biochem Mol Toxicol; 2018 Feb; 32(2):. PubMed ID: 29315967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
